Company intelligence / Profile preview

Luzitin

Coimbra / São Martinho do Bispo, Centro Region / Coimbra District, Portugalluzitin.pt ↗

Ownership: Private
Development stage: Phase 2

Overview

Redaporfin demonstrated safety, tolerability, and efficacy signals in a proof-of-concept trial for advanced head and neck cancer. The drug has orphan drug designation from the EMA for biliary tract cancer. A pivotal Phase III trial is being planned.[3][6] LUZACNE program targeting moderate to severe acne remains at an early stage.

Therapeutic areas: OncologyDermatology
Modalities: Photosensitizing small molecules (photosensitizers) for photodynamic therapy (PDT) and photodiagnosis (PDD)[1][2][4][5]
Industry: Biotech

Drug pipeline

1 asset

redaporfin

Partnerships

University of CoimbraBluepharma S.A.InovCapital/Portugal Ventures S.A.[5]seeking licensing partners at BIO-Europe/BIO International events[3]academic collaborations with Coimbra University Hospitals

Beyond the preview

Go deeper on Luzitin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luzitin.

Explore the full profile